Patents by Inventor Hamid Rabb

Hamid Rabb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240408114
    Abstract: Provided are glutamine antagonists and prodrugs of glutamine analogs having formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in preventing and/or treating acute kidney injury.
    Type: Application
    Filed: November 4, 2022
    Publication date: December 12, 2024
    Inventors: Hamid RABB, Barbara SLUSHER, Jonathan D. POWELL, Kyungho LEE, Elizabeth THOMPSON, Sanjeev NOEL, Sepideh GHARAIE
  • Publication number: 20200120909
    Abstract: The present invention relates to the field of nephrology. More specifically, the present invention provides compositions and methods useful for the study and treatment of acute kidney injury. In one embodiment, the present invention provides a knockout animal whose genome comprises a deletion of exon 2 and exon 3 of kelch-like ECH-associated protein 1 (KEAP1) in T-cells. In another embodiment, a method for treating a subject diagnosed with AKI comprising the steps of (a) isolating T-cells from the subject; (b) activating Nrf2 expression in the isolated T-cells; and (c) administering the T-cells back to the subject.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 23, 2020
    Inventors: Hamid Rabb, Sanjeev Noel, Maria N. Martina-Lingua, Lorraine C. Racusen, Abdel Rahim Hamad, Samatha Bandapalle
  • Publication number: 20160120158
    Abstract: The present invention relates to the field of nephrology. More specifically, the present invention provides compositions and methods useful for the study and treatment of acute kidney injury. In one embodiment, the present invention provides a knockout animal whose genome comprises a deletion of exon 2 and exon 3 of kelch-like ECH-associated protein 1 (KEAP1) in T-cells. In another embodiment, a method for treating a subject diagnosed with AKI comprising the steps of (a) isolating T-cells from the subject; (b) activating Nrf2 expression in the isolated T-cells; and (c) administering the T-cells back to the subject.
    Type: Application
    Filed: November 3, 2015
    Publication date: May 5, 2016
    Inventors: Hamid Rabb, Sanjeev Noel, Maria N. Martina-Lingua, Lorraine C. Racusen, Abdel Rahim Hamad, Samatha Bandapalle
  • Publication number: 20110150879
    Abstract: Specific depletion or modulation of activity of CD4? T cells is used to treat and/or prevent damage due to ischemia of kidneys, heart, brain. It also has been found to reduce rejection of transplanted organs. The donor, recipient, or isolated organ can be so treated.
    Type: Application
    Filed: December 20, 2010
    Publication date: June 23, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Hamid RABB
  • Publication number: 20090142357
    Abstract: Specific depletion or modulation of activity of CD4+ T cells is used to treat and/or prevent damage due to ischemia of kidneys, heart, brain. It also has been found to reduce rejection of transplanted organs. The donor, recipient, or isolated organ can be so treated.
    Type: Application
    Filed: October 30, 2008
    Publication date: June 4, 2009
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Hamid Rabb
  • Publication number: 20080069795
    Abstract: Kidney toxicity which is induced by cisplatin and other therapeutic and diagnostic agents, limits the effectiveness of the therapy or diagnosis. Modulation or depletion of T cells ameliorates the toxicity, permitting the use of cisplatin at levels and for durations which treat cancers more effectively. Modulation and depletion can be accomplished using antibodies for T cell surface antigens as well as using other molecules which effectively antagonize or down-regulate the cytokines and/or chemokines which T cells elaborate.
    Type: Application
    Filed: June 29, 2005
    Publication date: March 20, 2008
    Applicant: The John Hopkins University
    Inventor: Hamid Rabb
  • Publication number: 20050106138
    Abstract: Specific depletion or modulation of activity of CD4+ T cells is used to treat and/or prevent damage due to ischemia of kidneys, heart, brain. It also has been found to reduce rejection of transplanted organs. The donor, recipient, or isolated organ can be so treated.
    Type: Application
    Filed: September 18, 2002
    Publication date: May 19, 2005
    Inventor: Hamid Rabb